Previous close | 2.1900 |
Open | 2.1850 |
Bid | 2.0100 x 3700 |
Ask | 2.0400 x 7400 |
Day's range | 2.0000 - 2.1900 |
52-week range | 1.2500 - 14.5500 |
Volume | |
Avg. volume | 11,003,241 |
Market cap | 550.159M |
Beta (5Y monthly) | 1.98 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Ambry Genetics, a prominent leader in clinical genomic testing and a subsidiary of REALM IDx, Inc., along with PacBio (NASDAQ: PACB), a leading developer of high-quality, highly accurate sequencing solutions, today announced their companies' selection by the University of California, Irvine (UCI) and the GREGoR Consortium (Genomics Research to Elucidate the Genetics of Rare diseases) to support the Pediatric Mendelian Genomics Research Center (MGRC) program to better understand the underlying bi
PacBio (NASDAQ: PACB) today announced financial results for the quarter ended March 31, 2024.
Announces Plan to Reduce Annualized Operating Expense Run Rate by $50 - $75 Million